Kyverna Therapeutics, Inc.
miv-cel
generalized myasthenia gravis
Date
TBD
Phase 3 readout · Date TBD estimated
What's at stake
Phase 3 trial results for miv-cel in generalized myasthenia gravis are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“Building on unprecedented interim Phase 2 data, Kyverna will continue to advance enrollment for the Phase 3 portion of the KYSA-6 clinical trial.”